Skip to main content

Medicare Clinical Laboratory Fee Schedule 2026 (October)

Medicare Part B pays clinical diagnostic laboratory tests from their own fee schedule, the CLFS, rather than from the physician fee schedule. This page reads the fourth-quarter 2026 public use file (26CLABQ4, effective 2026-10-01) and summarizes its 2,243 rows by code range, lists every HCPCS Level II laboratory code with its CMS descriptor, and shows what changed since July. CPT numbers, including proprietary laboratory analyses and multianalyte assay codes, appear only as numbers with their payment amounts.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Clinical Laboratory Fee Schedule: 26CLABQ4 (CY2026 Q4) (effective October 1, 2026); HCPCS Level II file: October 2026 (effective October 1, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

TL;DR

The October 2026 Clinical Laboratory Fee Schedule (26CLABQ4) lists 2,243 code and modifier rows for 2,117 laboratory test codes: 2,125 rows carry a national payment amount and 118 are priced locally by the Medicare Administrative Contractor. National amounts for the base codes run from $2.17 to $12,000.00 with a median of $35.09. The file adds 40 rows since the July release, all of them proprietary laboratory analyses (PLA) codes, and drops 3; 126 rows repeat a code with modifier QW for CLIA-waived testing.

The October 2026 file in numbers

Code and modifier rows
2,243
2,117 distinct codes
National payment amounts
2,125
118 rows priced by the contractor
CLIA-waived (QW) rows
126
126 at the same amount as the base code
PLA codes
617
four digits and U
HCPCS Level II lab codes
42
G, P, Q and U codes
Median national amount
$35.09
$2.17 to $12,000.00

Each row of the file carries the year, the code, an optional modifier, the date the amount took effect, a pricing indicator and the payment rate. The indicator is N when CMS sets a national payment amount that every Medicare Administrative Contractor pays, and L when the code is priced locally by the Medicare Administrative Contractor; locally priced rows show a rate of zero in the file. Most rows took effect on January 1, 2026; 88 rows carry a later date (1 on 2026-03-24, 17 on 2026-04-01, 1 on 2026-05-15, 30 on 2026-07-01, 39 on 2026-10-01), the quarterly additions CMS makes as new codes are created.

How Medicare pays a laboratory test

The CLFS is a single national schedule: unlike the physician fee schedule there are no geographic practice cost indices and no locality adjustment, so a test pays the same national amount in Manhattan and in rural Arkansas. Part B pays the lesser of the amount the laboratory bills and the fee schedule amount, and clinical diagnostic laboratory tests carry neither the Part B deductible nor coinsurance, so the amount in the file is what Medicare pays for a covered test. Since 2018 most national amounts have been set from the private payer rates that applicable laboratories report to CMS under the Protecting Access to Medicare Act of 2014 (section 1834A of the Social Security Act), using a weighted median of those rates for each code.

A laboratory test is paid from the CLFS only when it is billed on its own. The professional component of certain pathology services is a physician fee schedule service, tests furnished during an inpatient stay are bundled into the MS-DRG payment, and tests on a hospital outpatient claim are usually packaged into the OPPS payment for the visit or procedure (status indicator Q4 marks laboratory codes that are packaged unless they are the only services on the claim). The Medicare fee lookup returns the CLFS amount, the physician fee schedule row and the OPPS status indicator for a code side by side, so the three answers can be compared.

National amounts by code range

The base rows (without modifier QW) grouped by code range. Chemistry has the most codes (411, median $14.78), while the molecular and proprietary ranges carry the highest amounts: molecular pathology and genomic codes have a median of $274.83 and PLA codes $634.84, with 114 PLA codes still priced locally.

Clinical Laboratory Fee Schedule October 2026: codes and national payment amounts by code range
Code rangeCodesLocalMedianLowest to highest
Organ and disease panels80047-8008110—$11.98$7.01 to $74.86
Drug testing and therapeutic drug levels80143-8037757—$16.59$6.61 to $62.14
Evocative and suppression testing80400-8043923—$86.96$32.62 to $801.62
Urinalysis81000-8109910—$3.56$2.17 to $29.98
Molecular pathology, genomic sequencing and multianalyte assays81105-815993071$274.83$35.00 to $12,000.00
Chemistry82009-84999411—$14.78$3.28 to $128.92
Hematology and coagulation85002-8599996—$9.79$2.37 to $80.46
Immunology and transfusion medicine86000-86999223—$14.05$2.99 to $357.56
Microbiology87003-879992412$22.75$4.27 to $679.77
Anatomic pathology, cytopathology and other laboratory procedures88000-8939863—$21.42$4.27 to $264.34
Proprietary laboratory analyses (PLA codes, four digits and U)0001U-0999U617114$634.84$4.48 to $8,500.00
Multianalyte assays with algorithmic analyses (four digits and M)0001M-0999M14—$736.20$79.00 to $3,489.63
HCPCS Level II laboratory codesG, P, Q and U codes421$19.31$4.27 to $246.92
Other codes outside the laboratory code ranges3—$11.06$9.34 to $94.41
Range labels describe the code numbers in plain words; they are not AMA section headings or code descriptors.

How the national amounts are spread

Distribution of CLFS national payment amounts, October 2026
National amountCodes
$0 to under $10283
$10 to under $25586
$25 to under $50240
$50 to under $100105
$100 to under $250212
$250 to under $500179
$500 to under $1,000179
$1,000 and over215

HCPCS Level II laboratory codes on the CLFS

42 HCPCS Level II codes are priced on the laboratory schedule: Medicare screening tests such as G0103, G0328 and the HIV and hepatitis screening codes, cervical cytopathology in G0123-G0148 and P3000, definitive drug testing in G0480-G0483 and G0659, specimen collection codes G0471 and P9612, the older chemistry tests in P2028-P2038, microscopy in Q0111-Q0115, and U0001 and U0002 for COVID-19 testing. Descriptors are CMS's HCPCS Level II descriptors from the October 2026 file; codes with an indexed reference page link to it.

HCPCS Level II codes on the Clinical Laboratory Fee Schedule, October 2026
CodeDescriptorRatePricing
G0027Semen analysis; presence and/or motility of sperm excluding huhner$6.50N
G0103Prostate cancer screening; prostate specific antigen test (psa)$19.31N
G0123Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision$20.26N
G0143Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision$27.05N
G0144Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision$43.97N
G0145Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision$26.49N
G0147Screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision$18.54N
G0148Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening$31.94N
G0306Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count$7.77N
G0307Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count)$6.47N
G0327Colorectal cancer screening; blood-based biomarkerlocalL
G0328Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneousAlso listed with QW (CLIA-waived)$18.05N
G0432Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening$19.57N
G0433Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screeningAlso listed with QW (CLIA-waived)$18.29N
G0435Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening$11.98N
G0471Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)$11.34N
G0472Hepatitis c antibody screening, for individual at high risk and other covered indication(s)Also listed with QW (CLIA-waived)$46.35N
G0475Hiv antigen/antibody, combination assay, screeningAlso listed with QW (CLIA-waived)$24.08N
G0476Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test$35.09N
G0480Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed$114.43N
G0481Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed$156.59N
G0482Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed$198.74N
G0483Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed$246.92N
G0499Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result$28.27N
G0567Infectious agent detection by nucleic acid (dna or rna); hepatitis c, screening, amplified probe techniqueAlso listed with QW (CLIA-waived)$35.09N
G0659Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes$62.14N
G9143Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)$120.72N
P2028Cephalin floculation, blood$4.95N
P2029Congo red, blood$4.95N
P2031Hair analysis (excluding arsenic)$4.95N
P2033Thymol turbidity, blood$4.95N
P2038Mucoprotein, blood (seromucoid) (medical necessity procedure)$4.95N
P3000Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision$18.54N
P9612Catheterization for collection of specimen, single patient, all places of service$9.34N
P9615Catheterization for collection of specimen(s) (multiple patients)$9.34N
Q0111Wet mounts, including preparations of vaginal, cervical or skin specimens$18.54N
Q0112All potassium hydroxide (koh) preparations$5.83N
Q0113Pinworm examinations$4.27N
Q0114Fern test$9.74N
Q0115Post-coital direct, qualitative examinations of vaginal or cervical mucous$25.00N
U0001Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel$35.92N
U00022019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdcAlso listed with QW (CLIA-waived)$51.31N

The highest national amounts

The fifteen highest national amounts on the October file all belong to molecular, genomic, multianalyte or proprietary laboratory tests. They are CPT numbers, shown without descriptors; open one in the fee lookup to see its CLFS row with any QW variant and its OPPS status.

Codes with the highest CLFS national payment amounts, October 2026
CodeCode typeNational amountEffective
81416CPT number$12,000.002026-01-01
0315UPLA (CPT number)$8,500.002026-01-01
0211UPLA (CPT number)$8,455.002026-01-01
81552CPT number$7,776.002026-01-01
0094UPLA (CPT number)$7,582.202026-01-01
0426UPLA (CPT number)$7,582.202026-01-01
0582UPLA (CPT number)$7,582.202026-01-01
81529CPT number$7,193.002026-01-01
0267UPLA (CPT number)$6,739.332026-01-01
0265UPLA (CPT number)$5,475.802026-01-01
0212UPLA (CPT number)$5,475.202026-01-01
0295UPLA (CPT number)$5,435.002026-01-01
81554CPT number$5,409.602026-01-01
0214UPLA (CPT number)$5,224.602026-01-01
0335UPLA (CPT number)$5,224.602026-01-01

What changed from July to October 2026

Comparing the fourth-quarter file with the third-quarter file (26CLABQ3, 2,206 rows) row by row, 40 rows are new, 3 are gone and no rate on a row present in both files changed. 39 of the new rows take effect on October 1, 2026; 39 of them are priced locally until CMS sets a national amount, the rest carry an earlier effective date because CMS added them retroactively to the date the code became valid.

Rows added to the Clinical Laboratory Fee Schedule between the July and October 2026 files
CodeCode typeModifierEffectiveRate
0442UPLA (CPT number)QW2026-03-24$41.38
0660UPLA (CPT number)—2026-10-01local
0661UPLA (CPT number)—2026-10-01local
0662UPLA (CPT number)—2026-10-01local
0663UPLA (CPT number)—2026-10-01local
0664UPLA (CPT number)—2026-10-01local
0665UPLA (CPT number)—2026-10-01local
0666UPLA (CPT number)—2026-10-01local
0667UPLA (CPT number)—2026-10-01local
0668UPLA (CPT number)—2026-10-01local
0669UPLA (CPT number)—2026-10-01local
0670UPLA (CPT number)—2026-10-01local
0671UPLA (CPT number)—2026-10-01local
0672UPLA (CPT number)—2026-10-01local
0673UPLA (CPT number)—2026-10-01local
0674UPLA (CPT number)—2026-10-01local
0675UPLA (CPT number)—2026-10-01local
0676UPLA (CPT number)—2026-10-01local
0677UPLA (CPT number)—2026-10-01local
0678UPLA (CPT number)—2026-10-01local
0679UPLA (CPT number)—2026-10-01local
0680UPLA (CPT number)—2026-10-01local
0681UPLA (CPT number)—2026-10-01local
0682UPLA (CPT number)—2026-10-01local
0683UPLA (CPT number)—2026-10-01local
0684UPLA (CPT number)—2026-10-01local
0685UPLA (CPT number)—2026-10-01local
0686UPLA (CPT number)—2026-10-01local
0687UPLA (CPT number)—2026-10-01local
0688UPLA (CPT number)—2026-10-01local
0689UPLA (CPT number)—2026-10-01local
0690UPLA (CPT number)—2026-10-01local
0691UPLA (CPT number)—2026-10-01local
0692UPLA (CPT number)—2026-10-01local
0693UPLA (CPT number)—2026-10-01local
0694UPLA (CPT number)—2026-10-01local
0695UPLA (CPT number)—2026-10-01local
0696UPLA (CPT number)—2026-10-01local
0697UPLA (CPT number)—2026-10-01local
0698UPLA (CPT number)—2026-10-01local

No longer on the October file: 0556U ($142.63 in July), 0557U ($262.99 in July), 0585U ($2,919.60 in July).

Laboratory NCDs and their national amounts

The 23 laboratory national coverage determinations govern common tests through a national edit: the procedure codes each one names are paid only when the claim carries a diagnosis the NCD's ICD-10-CM list supports. 23 of them name codes with a national amount on this file. Each NCD page lists its procedure codes with these amounts and the covered and non-covered diagnosis codes.

Billing notes that change the amount

Modifier QW tells the contractor that a test on the CLIA-waived list was performed by a laboratory holding a certificate of waiver; without it, a waived laboratory's claim for that test is denied for CLIA reasons even though the amount is the same. Medically unlikely edits cap the units of many laboratory codes per day, and NCCI procedure-to-procedure edits bundle component tests into panels, so the MUE lookup and the NCCI checker answer the questions a lab line raises before it is priced. Coverage for tests outside the national laboratory NCDs is decided locally; the LCD lookup finds the contractor policies that list a code.

Hospital laboratories that bill on the 13x outpatient type of bill use the same CLFS amounts for tests that are not packaged, and the OPPS status indicator page explains when the Q4 conditional packaging applies. Other fee schedules on this site: the physician fee schedule for pathology interpretations and the fee schedules hub for the full map.

Where QuickIntell fits for laboratory claims

QuickRCM covers eligibility, claim readiness, denials and posting with configurable automation and human review, which is where a missing QW modifier, an unsupported diagnosis under a lab NCD or a unit limit is caught before the claim goes out.

Frequently asked questions

What is the Medicare Clinical Laboratory Fee Schedule?

The fee schedule Medicare Part B uses to pay clinical diagnostic laboratory tests. CMS publishes it quarterly; the fourth quarter 2026 file (26CLABQ4) has 2,117 codes, 2,075 of them CPT numbers (including 617 proprietary laboratory analyses codes and 14 multianalyte assay codes) and 42 HCPCS Level II codes. Since 2018 most national amounts are set from private payer rates that laboratories report to CMS under the Protecting Access to Medicare Act.

Do Medicare patients pay coinsurance for lab tests?

No. Clinical diagnostic laboratory tests paid under the CLFS carry no Part B deductible and no coinsurance, and Part B pays the lesser of the amount billed and the fee schedule amount. Laboratory services furnished as part of another payment, such as a hospital inpatient stay, are paid under that system instead.

What does indicator L mean in the CLFS file?

L means the code is priced locally: the Medicare Administrative Contractor sets the payment, and the file shows $0.00 for it. 118 rows carry L this quarter, 118 of them with a zero rate. N marks a national payment amount that every contractor pays.

What is modifier QW on the lab fee schedule?

QW identifies a test performed under a CLIA certificate of waiver. The 26CLABQ4 file lists 126 QW rows, and 126 of them carry the same amount as the code without the modifier, so the modifier marks a test run under a waiver rather than changing the amount.

How many lab codes were added to the CLFS in October 2026?

40 rows appear in the October file that were not in the July file (39 effective October 1, 2026), 3 rows were dropped, and no rate on a code present in both files changed.

Is specimen collection paid on the lab fee schedule?

Some collection services are. G0471, collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha), is on the 26CLABQ4 file at $11.34. Routine venipuncture is billed with its CPT number, which is also on the file.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-10. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

Operational reference compiled from the CMS Clinical Laboratory Fee Schedule public use files for July and October 2026. Amounts are Medicare national payment amounts; Medicare Advantage, Medicaid and commercial plans set their own rates. CPT, PLA and MAAA codes appear as bare numbers; CPT descriptors are copyright AMA and are not shown. Not legal, coding or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.